BTRX-246040 Completed Phase 2 Trials for Major Depressive Disorder (MDD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03193398BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
NCT01724112Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)